SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing intense selling pressure following a quarterly report that revealed significant headwinds in China and ongoing concerns regarding the impact of tariffs on margins. Investors are actively debating the company's long-term relevance and the effectiveness of management's turnaround efforts, with many expressing frustration over the stock's persistent decline compared to its historical performance.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential amid significant leadership changes and a shift toward U.S.-based institutional operations. While some users express frustration over stagnant price action and recent market lows, a vocal segment of the community remains focused on the project's real-world utility, recent regulatory clarity, and its ongoing efforts to scale institutional adoption.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is drawing significant attention as traders debate whether its small asset base and exposure to SpaceX represent a promising new momentum play or a potential risk. Community discussion is sharply divided, with some investors eyeing the ticker for its high-volatility potential and similarities to recent thematic ETF surges, while others express skepticism over its low assets under management and limited holdings.

Ganymede

Ganymede is drawing attention as market participants highlight its clean structural formation and consistent buyer interest, fueling community optimism about its potential for growth. Traders are actively discussing the token's quiet momentum and controlled price action, viewing current levels as a favorable accumulation phase.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is surging following the FDA approval of EMPAVELI for the treatment of rare kidney diseases, marking a significant milestone that investors hope will validate the company's immunology pipeline. The community is actively discussing the stock's potential for a broader recovery, with many bulls focusing on the commercial opportunity in the nephrology space and speculating on whether this momentum might finally trigger long-awaited interest from potential acquirers.

Maul Coin

Maul Coin is trending as the community rallies around a creator-backed project, actively promoting it across social platforms to drive volume and secure a listing. Supporters are focused on organic growth and the potential for a community-led breakout, while closely monitoring market activity following recent whale selling.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea following recent FDA approval and look ahead to upcoming earnings for initial revenue insights. Community discussion remains focused on the company's strong cash position, the strategic potential of the Novo Nordisk partnership, and anticipation of a potential squeeze as market participants weigh long-term value against ongoing short interest.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is currently experiencing heightened community debate as investors weigh speculative partnerships and institutional growth prospects against concerns over high-volume sell-offs and pump-and-dump behavior. While some proponents view recent price volatility as an accumulation opportunity ahead of anticipated network updates and infrastructure rollouts, others remain skeptical about the project's long-term transparency and real-world adoption.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following a surge in trading volume and investor interest after the company entered a clinical development collaboration with Pfizer for its prostate cancer program, ORIC-533. The community is actively discussing the stock's potential for a short squeeze, citing high short interest and institutional confidence bolstered by the recent strategic investment.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is experiencing intense volatility as investors debate the impact of conflicting geopolitical headlines, specifically regarding potential military escalation in the Middle East and market manipulation concerns. Community sentiment is deeply divided, with traders actively weighing the risk of a market-wide correction against the effectiveness of current government-led de-escalation narratives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


dagatructiepkim

đá gà trực tiếp